Interactive explainers
How treatment actually evolved, trial by trial.
Interactive timelines across blood disorders and cancers — disease by disease, and now by therapy. Each is built from primary literature, ClinicalTrials.gov, and FDA/EMA records, and written to be understood by patients and useful to clinicians.
The CAR-T Cell Therapy Landscape
A modality, not a single disease — every FDA-approved CAR-T and the pivotal trials behind it, from the first CD19 approvals in leukemia and lymphoma, through BCMA and GPRC5D in myeloma, out to the allogeneic “off‑the‑shelf” and solid‑tumor frontier. Swimlanes are target antigens; toggle the allogeneic thread.
Open the landscape Multiple MyelomaFour Decades of Myeloma Therapy
From melphalan to CAR-T — the trials that turned a two-to-three-year prognosis into a disease many people live with for decades. Trace each approval and the survival curve that climbed with it.
Open the timeline CLL / SLLCLL/SLL Treatment Timeline
The shift from chemotherapy to targeted, fixed-duration, chemo-free care — including the del(17p)/TP53 thread that reshaped how we treat high-risk disease.
Open the landscape Waldenström MacroglobulinemiaSix Decades of Waldenström Therapy
From alkylators and rituximab chemoimmunotherapy to the BTK-inhibitor era of ibrutinib and zanubrutinib — the first drugs ever approved for this rare IgM lymphoma. Toggle the MYD88 L265P / CXCR4 thread that governs BTK-inhibitor response.
Open the timeline Mantle Cell LymphomaFrom Chemotherapy to CAR-T in Mantle Cell Lymphoma
How a historically chemo-defined lymphoma was remade by targeted and cellular therapy — from R‑CHOP and high‑dose cytarabine through the BTK inhibitors and CD19 CAR‑T, including the ibrutinib indication the FDA withdrew and the TRIANGLE result that is retiring routine transplant. Toggle the TP53‑mutated high-risk thread.
Open the timeline Diffuse Large B-Cell LymphomaFrom R-CHOP to CAR-T: The DLBCL Timeline
The most common aggressive lymphoma — a curative R‑CHOP first line that resisted improvement for two decades while relapsed disease was remade by anti‑CD79b and anti‑CD19 antibody‑drug conjugates, CD19 CAR‑T, and CD20×CD3 bispecifics — including the selinexor approval the FDA withdrew in 2026. Toggle the relapsed/refractory thread.
Open the timeline Acute Myeloid LeukemiaFrom 7+3 to Targeted Therapy
Four decades of the “7+3” chemo backbone, then the 2017 explosion of targeted drugs — FLT3, IDH, and menin inhibitors, plus venetoclax — that turned AML into a mutation-directed disease. Toggle the actionable-mutation thread.
Open the timeline Chronic Myeloid LeukemiaCML Treatment Timeline
The disease that defined targeted therapy — from busulfan and interferon to imatinib and the BCR::ABL1 tyrosine-kinase inhibitors, the pan-inhibitor ponatinib, and the allosteric STAMP inhibitor asciminib, alongside the move toward treatment-free remission. Toggle the T315I gatekeeper-mutation thread that governs which drugs still work.
Open the timeline Lung Cancer (NSCLC)From Chemotherapy to Precision in NSCLC
How advanced non–small cell lung cancer went from one-size-fits-all platinum chemotherapy to biomarker-driven care — EGFR, ALK, ROS1, KRAS G12C and more — and the checkpoint immunotherapy era layered on top. Filter the timeline by molecular driver.
Open the timeline Lung Cancer (SCLC)The Immunotherapy Turn in Small Cell Lung Cancer
Decades of the platinum–etoposide backbone with topotecan as the only second-line option, then the checkpoint-immunotherapy era in extensive-stage disease and the arrival of DLL3 T-cell engagers — tarlatamab — in relapsed disease. Toggle the limited-stage, curative-intent thread.
Open the timeline Cervical CancerCervical Cancer Treatment Timeline
From cisplatin chemoradiation and platinum doublets through the bevacizumab and PD‑1/PD‑L1 checkpoint eras to the tisotumab vedotin antibody‑drug conjugate. Toggle the PD‑L1 (CPS ≥1) thread that gates checkpoint-inhibitor benefit.
Open the timeline Endometrial (Uterine) CancerEndometrial Cancer Treatment Timeline
From progestins and the carboplatin/paclitaxel chemotherapy backbone to the frontline checkpoint-inhibitor revolution — dostarlimab, pembrolizumab, and durvalumab — that reorganized care around molecular subtype. Toggle the dMMR / MSI‑H thread that gates immunotherapy benefit.
Open the timeline Ovarian CancerThe Maintenance Era of Ovarian Cancer
From the platinum and platinum–taxane chemotherapy backbone through anti‑angiogenic bevacizumab to the PARP‑inhibitor maintenance revolution and the folate‑receptor‑α antibody‑drug conjugate. Toggle the BRCA / HRD thread that gates PARP‑inhibitor benefit.
Open the timeline Colon CancerThe Biomarker Era of Colon Cancer
From the 5‑FU / leucovorin backbone through oxaliplatin and irinotecan doublets, anti‑VEGF and anti‑EGFR antibodies, to biomarker-directed care — BRAF, HER2, KRAS G12C, and MSI‑H/dMMR immunotherapy. Toggle the MSI‑H / dMMR thread that unlocks chemo-free frontline treatment.
Open the timeline Rectal CancerThe Organ-Preservation Era of Rectal Cancer
From total mesorectal excision and preoperative chemoradiation to total neoadjuvant therapy, watch-and-wait organ preservation, and the dMMR immunotherapy that can erase surgery entirely — plus the biomarker-targeted agents (BRAF, HER2, KRAS G12C) for metastatic disease. Toggle the dMMR / MSI‑H thread.
Open the timeline Esophageal & GEJ CancerEsophageal & GEJ Cancer Treatment Timeline
From the cytotoxic 5‑FU/platinum backbone and neoadjuvant chemoradiation through HER2 and anti‑angiogenic targeting to the PD‑1 checkpoint era and the newest HER2 antibody‑drug conjugate and Claudin 18.2 agents. Toggle the squamous cell (ESCC) thread that separates it from adenocarcinoma — the split that drives every drug choice.
Open the timeline Gastric & GEJ CancerGastric & GEJ Cancer Treatment Timeline
From the fluoropyrimidine–platinum chemotherapy backbone and perioperative FLOT through the first biomarker breakthrough with HER2‑targeted trastuzumab, VEGFR2 blockade, the PD‑1 checkpoint era, and the new Claudin 18.2 agents and perioperative immunotherapy. Toggle the biomarker-selected thread that separates targeted and immunotherapy agents from unselected chemo.
Open the timeline AnticoagulationThe Anticoagulation Arc
A century of trading clotting risk against bleeding — from heparin and warfarin through the DOAC era to the Factor XI inhibitors designed to separate thrombosis from hemostasis.
Open the timeline Iron DeficiencyThe Evolution of Iron Deficiency Treatment
From 19th-century ferrous salts through the iron-dextran era and its anaphylaxis risk to modern single-visit IV formulations — the safety signals and hepcidin science that reshaped how we replete iron. Toggle oral vs. IV.
Open the timeline